Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China.
Department of Obstetrics and Gynecology, Suzhou Municipal Hospital, Suzhou, China.
J Cell Biochem. 2019 Apr;120(4):6237-6249. doi: 10.1002/jcb.27911. Epub 2018 Oct 18.
Nuclear receptor coactivator 5 (NCOA5) specifically enhances estrogen receptor α-modulated transcriptional activity. As a novel tumor suppressor, depletion of NCOA5 is associated with the development of a variety of tumors, but its function in cervical cancer is currently unclear. In this study, we addressed how expression of NCOA5 changed in the development of human cervical cancer and its association with clinicopathological features, prognosis, and biology characteristics of cervical cancer. Analysis of the microarrays in the Oncomine database indicated that NCOA5 expression was lower in human cervical squamous cell carcinoma tissues than that in normal cervical tissues. That was corroborated by our experiments using fresh tissues: the expression levels of NCOA5 messenger RNA and protein were both significantly decreased in cervical cancer tissues compared with paired adjacent nontumor tissues (P < 0.01). Low expression of NCOA5 is associated with the International Federation of Gynecology and Obstetrics stage ( P = 0.043) and histological grade ( P = 0.018) of human cervical cancer. In addition, patients possessing low NCOA5 expression had poorer prognosis. Univariate and multivariate Cox regression analyses indicated that low NCOA5 expression may be an independent prognostic factor for poorer overall survival in cervical cancer. Further, downregulation of NCOA5 expression results in a significant increase in proliferation, migration, and invasion of HeLa cells. Data of xenograft tumor on BALB/c nude mice manifested that HeLa cells with low NCOA5 expression tend to form larger tumors than negative control ones. In contrast, overexpression of NCOA5 expression leads to the opposite results. Finally, we found that NCOA5 might affect the biological function of human cervical cancer cells by mediating the notch3 signaling pathway. These findings suggest that NCOA5 acts as a tumor suppressor to inhibit tumorigenicity, migration, and invasion, and thus represents a potential novel prognostic marker for overall survival in cervical cancer.
核受体辅激活因子 5(NCOA5)特异性增强雌激素受体 α 调节的转录活性。作为一种新的肿瘤抑制因子,NCOA5 的缺失与多种肿瘤的发生发展有关,但它在宫颈癌中的作用尚不清楚。在这项研究中,我们研究了 NCOA5 在人宫颈癌发展过程中的表达变化及其与宫颈癌临床病理特征、预后和生物学特征的关系。Oncomine 数据库中的微阵列分析表明,NCOA5 在人宫颈鳞状细胞癌组织中的表达低于正常宫颈组织。我们使用新鲜组织进行的实验也证实了这一点:与配对的相邻非肿瘤组织相比,宫颈癌组织中 NCOA5 信使 RNA 和蛋白的表达水平均显著降低(P<0.01)。NCOA5 低表达与国际妇产科联合会(FIGO)分期(P=0.043)和组织学分级(P=0.018)有关。此外,NCOA5 低表达的患者预后较差。单因素和多因素 Cox 回归分析表明,NCOA5 低表达可能是宫颈癌总生存的独立预后因素。进一步下调 NCOA5 表达可显著增加 HeLa 细胞的增殖、迁移和侵袭。BALB/c 裸鼠异种移植肿瘤的数据表明,NCOA5 低表达的 HeLa 细胞比阴性对照的 HeLa 细胞更容易形成较大的肿瘤。相反,过表达 NCOA5 表达会导致相反的结果。最后,我们发现 NCOA5 可能通过调节 Notch3 信号通路影响人宫颈癌细胞的生物学功能。这些发现表明,NCOA5 作为一种肿瘤抑制因子,抑制肿瘤发生、迁移和侵袭,因此可能成为宫颈癌总生存的潜在新型预后标志物。